Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Management of postoperative ileus: focus on alvimopan

Authors Eric L Marderstein, Conor P Delaney

Published Date August 2008 Volume 2008:4(5) Pages 965—973

DOI http://dx.doi.org/10.2147/TCRM.S3147

Published 18 August 2008

Eric L Marderstein, Conor P Delaney

Division of Colorectal Surgery, Department of Surgery, University Hospitals Case Medical Center, Case Western, Reserve School of Medicine, Cleveland, Ohio, USA

Abstract: Postoperative ileus (POI) is a transient loss of coordinated peristalsis precipitated by surgery and exacerbated by opioid pain medication. Ileus causes a variety of symptoms including bloating, pain, nausea, and vomiting, but particularly delays tolerance of oral diet and liquids. Thus POI is a primary determinant of hospital stay after surgery. ‘Fast-track’ recovery protocols, opioid sparing analgesia, and laparoscopic surgery reduce but do not eliminate postoperative ileus. Alvimopan is a mu opioid receptor antagonist that blocks the effects of opioids on the intestine, while not interfering with their centrally mediated analgesic effect. Several large randomized clinical trials have demonstrated that alvimopan accelerates the return of gastrointestinal function after surgery and subsequent hospital discharge by approximately 20 hours after elective open segmental colectomy. However, it has not been tested in patients undergoing laparoscopic surgery and is less effective in patients receiving nonsteroidal antiinflammatory agents in a narcotic sparing postoperative pain control regimen. Safety concerns seen with chronic low dose administration of alvimopan for opioid bowel dysfunction have not been noted with its acute use for POI.

Keywords: alvimopan, postoperative ileus, gastrointestinal surgery

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Use of the Microsoft Kinect system to characterize balance ability during balance training

Lim DH, Kim CY, Jung HH, Jung DY, Chun KJ

Clinical Interventions in Aging 2015, 10:1077-1083

Published Date: 30 June 2015

Effects of strontium ranelate on bone formation in the mid-palatal suture after rapid maxillary expansion

Zhao SY, Wang XX, Li N, Chen Y, Su YR, Zhang J

Drug Design, Development and Therapy 2015, 9:2725-2734

Published Date: 21 May 2015

A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects

Adar L, Avisar N, Lammerich A, Kleiman RB, Spiegelstein O

Drug Design, Development and Therapy 2015, 9:2653-2662

Published Date: 15 May 2015

Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma

Dogan B, Erol MK, Toslak D, Coban DT, Bulut M, Cengiz A, Sarı ES

Therapeutics and Clinical Risk Management 2015, 11:683-689

Published Date: 30 April 2015

Helicobacter pylori infection in Chinese patients with atrial fibrillation

Wang DZ, Chen W, Yang S, Wang J, Li Q, Fu Q, Li SJ, Chen BX

Clinical Interventions in Aging 2015, 10:813-819

Published Date: 28 April 2015

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Byeon HJ, Kim I, Choi JS, Lee ES, Shin BS, Youn YS

International Journal of Nanomedicine 2015, 10:739-748

Published Date: 19 January 2015